ClinicalTrials.gg
CompletedNCT00532935Updated Jun 9, 2017Results posted

MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)

A Phase 3 interventional study of sitagliptin phosphate (+) metformin hydrochloride and Comparator: pioglitazone in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-06-09.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
517
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
29th of 197
517 · median 102
Started
2008
with 22 others
Phase 3
74 of 198
none open now
Registered
33rd of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 29th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 74 in phase 3, and was the 33rd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A study to evaluate the efficacy and safety of MK0431A in comparison to a commonly used medication in patients with type 2 diabetes

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General Inclusion Criteria:

  • Patient has type 2 diabetes mellitus
  • Patient is inadequately controlled and not on treatment with insulin or oral antihyperglycemic therapy

General Exclusion Criteria:

  • Patient has a history of type 1 diabetes mellitus or history of ketoacidosis
  • Patient was on antihyperglycemic agent therapy (oral or insulin) within the prior 12 weeks
  • Patient was on >4 weeks (cumulatively) of antihyperglycemic therapy (oral or insulin) over the prior 3 years
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
517 participants (actual)

Study arms

  • Experimental
    1

    Sitagliptin phosphate (+) metformin hydrochloride

    Drug: sitagliptin phosphate (+) metformin hydrochloride

  • Active comparator
    2

    pioglitazone

    Drug: Comparator: pioglitazone

Interventions

  • Drugsitagliptin phosphate (+) metformin hydrochloride

    Drug pages: Sitagliptin · Metformin

    sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an \~32 wk treatment period

    Also known as: Janumet

  • pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an \~32-wk treatment period.

    Also known as: pioglitazone

06

What researchers measure

Primary outcomes

  1. Change From Baseline in A1C at Week 32

    A1C is measured as a percent. Thus this change from baseline reflects the Week 32 A1C percent minus the baseline A1C percent

    Time frame: Baseline and Week 32

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 1

    Change from baseline reflects the Week 1 FPG minus the baseline FPG. At Week 1, the dose was 50/500 mg b.i.d. for Sita/Met FDC and 30 mg q.d. for pioglitazone

    Time frame: Baseline and Week 1

  2. Change From Baseline in 2-hour Post-Meal Glucose (PMG) at Week 32

    Change from baseline reflects the Week 32 2-hour PMG minus the baseline 2-hour PMG

    Time frame: Baseline and Week 32

  3. Change From Baseline in FPG at Week 32

    Change from baseline reflects the Week 32 FPG minus the baseline FPG

    Time frame: Baseline and Week 32

  4. Percent of Participants With A1C <7.0% at Week 32

    Time frame: Week 32

07

Results

Posted Oct 18, 2010
Limitations and caveats
Unknown to the Sponsor and the investigators, two patients in the study were randomized twice (each at two different sites). Data for these patients were deemed unreliable and excluded from all analyses (efficacy and safety).

Participant flow

First Patient In: 19-Mar-2008 Last Patient Last Visit: 23-Oct-2009 Seventy-four medical clinics worldwide (19 sites in the United States, 31 in Eastern Europe, and 24 in the rest of the world).

Participant flow — Overall Study
MilestoneSitagliptin/Metformin Fixed-Dose CombinationPioglitazone
Started261256
Completed210204
Not completed5152
Withdrew: Adverse event1112
Withdrew: Lack of efficacy03
Withdrew: Lost to follow-up106
Withdrew: Physician decision45
Withdrew: Pregnancy10
Withdrew: Protocol violation42
Withdrew: Withdrawal by subject109
Withdrew: Protocol specific criteria1115

Outcome measures

PrimaryChange From Baseline in A1C at Week 32

A1C is measured as a percent. Thus this change from baseline reflects the Week 32 A1C percent minus the baseline A1C percent

Time frame:
Baseline and Week 32
Reported as:
Least squares mean · Percent of glycosylated hemoglobin (A1C)
Change From Baseline in A1C at Week 32
Percent of glycosylated hemoglobin (A1C)Sitagliptin/Metformin Fixed-Dose CombinationPioglitazone
Change From Baseline in A1C at Week 32-1.86 (-2.00 to -1.73)-1.39 (-1.53 to -1.26)
Statistical analysis
  • Sitagliptin/Metformin Fixed-Dose Combination vs Pioglitazone · ANCOVA · p = <0.001 · Mean difference (net): -0.47 · 95% CI -0.66 to -0.28ANCOVA model included a term for treatment and a covariate for the baseline A1C value.
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 1

Change from baseline reflects the Week 1 FPG minus the baseline FPG. At Week 1, the dose was 50/500 mg b.i.d. for Sita/Met FDC and 30 mg q.d. for pioglitazone

Time frame:
Baseline and Week 1
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 1
mg/dLSitagliptin/Metformin Fixed-Dose CombinationPioglitazone
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 1-40.5 (-44.1 to -36.9)-13.0 (-16.6 to -9.3)
Statistical analysis
  • Sitagliptin/Metformin Fixed-Dose Combination vs Pioglitazone · ANCOVA · p = <0.001 · Mean difference (net): -27.6 · 95% CI -32.7 to -22.4ANCOVA model included a term for treatment and a covariate for the baseline FPG value.
SecondaryChange From Baseline in 2-hour Post-Meal Glucose (PMG) at Week 32

Change from baseline reflects the Week 32 2-hour PMG minus the baseline 2-hour PMG

Time frame:
Baseline and Week 32
Reported as:
Least squares mean · mg/dL
Change From Baseline in 2-hour Post-Meal Glucose (PMG) at Week 32
mg/dLSitagliptin/Metformin Fixed-Dose CombinationPioglitazone
Change From Baseline in 2-hour Post-Meal Glucose (PMG) at Week 32-102.2 (-110.7 to -93.8)-82.0 (-90.4 to -73.7)
Statistical analysis
  • Sitagliptin/Metformin Fixed-Dose Combination vs Pioglitazone · ANCOVA · p = <0.001 · Mean difference (net): -20.2 · 95% CI -32.1 to -8.3ANCOVA model included a term for treatment and a covariate for the baseline 2-hour PMG value.
SecondaryChange From Baseline in FPG at Week 32

Change from baseline reflects the Week 32 FPG minus the baseline FPG

Time frame:
Baseline and Week 32
Reported as:
Least squares mean · mg/dL
Change From Baseline in FPG at Week 32
mg/dLSitagliptin/Metformin Fixed-Dose CombinationPioglitazone
Change From Baseline in FPG at Week 32-56.0 (-60.9 to -51.0)-44.0 (-49.1 to -39.0)
Statistical analysis
  • Sitagliptin/Metformin Fixed-Dose Combination vs Pioglitazone · ANCOVA · p = <0.001 · Mean difference (net): -11.9 · 95% CI -19.0 to -4.9ANCOVA model included a term for treatment and a covariate for the baseline FPG value.
SecondaryPercent of Participants With A1C <7.0% at Week 32
Time frame:
Week 32
Reported as:
Number · Percent Participants
Percent of Participants With A1C <7.0% at Week 32
Percent ParticipantsSitagliptin/Metformin Fixed-Dose CombinationPioglitazone
Percent of Participants With A1C <7.0% at Week 3257.343.5
Statistical analysis
  • Sitagliptin/Metformin Fixed-Dose Combination vs Pioglitazone · Regression, Logistic · p = <0.001 (Based on a test of the odds ratio = 1, comparing the odds of having A1C \<7.0% at Week 32 in the Sitagliptin/Metformin 50/1000 mg b.i.d. group vs. the Pioglitazone 45 mg q.d. group.) · Odds ratio (or): 2.0 · 95% CI 1.3 to 2.8This parameter estimate and 95% confidence interval correspond to the odds of having A1C \<7.0% at Week 32 in the Sitagliptin/Metformin 50/1000 mg b.i.d. group vs. the Pioglitazone 45 mg q.d. group.

Adverse events

Collected over Week 0 through Week 32. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin/Metformin Fixed-Dose Combination—11/261 (4.2%)94/261 (36%)
Pioglitazone—8/256 (3.1%)68/256 (26.6%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventSitagliptin/Metformin Fixed-Dose CombinationPioglitazone
CholelithiasisHepatobiliary disorders3/2610/256
Upper gastrointestinal haemorrhageGastrointestinal disorders0/2611/256
PharyngitisInfections and infestations0/2611/256
PneumoniaInfections and infestations0/2611/256
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/2611/256
OsteoarthritisMusculoskeletal and connective tissue disorders0/2611/256
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2611/256
Urine flow decreasedRenal and urinary disorders0/2611/256
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/2611/256
Conjunctivitis allergicEye disorders1/2610/256
Most frequent other events
Most frequent other events
EventSitagliptin/Metformin Fixed-Dose CombinationPioglitazone
DiarrhoeaGastrointestinal disorders40/26111/256
HypoglycaemiaMetabolism and nutrition disorders22/26111/256
HeadacheNervous system disorders20/2617/256
Oedema peripheralGeneral disorders3/26118/256
Upper respiratory tract infectionInfections and infestations13/26117/256
NasopharyngitisInfections and infestations10/26116/256
DyspepsiaGastrointestinal disorders13/2612/256

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sitagliptin/Metformin Fixed-Dose CombinationPioglitazoneTotal
Mean52.4 ± 10.752.2 ± 1152.3 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin/Metformin Fixed-Dose CombinationPioglitazoneTotal
Female118122240
Male143134277
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Sitagliptin/Metformin Fixed-Dose CombinationPioglitazoneTotal
White168167335
Black6511
American Indian202
Asian5855113
Multi-racial272956
Hemoglobin A1C (A1C)
Hemoglobin A1C (A1C)(Percent of glycosylated hemoglobin (A1C))Sitagliptin/Metformin Fixed-Dose CombinationPioglitazoneTotal
Mean9.0 ± 1.38.9 ± 1.38.9 ± 1.3
Fasting Plasma Glucose (FPG)
Fasting Plasma Glucose (FPG)(mg/dL)Sitagliptin/Metformin Fixed-Dose CombinationPioglitazoneTotal
Mean190.6 ± 53.4188.9 ± 57.1189.8 ± 55.2
2-Hour Post-Meal Glucose (2-HR PMG)
2-Hour Post-Meal Glucose (2-HR PMG)(mg/dL)Sitagliptin/Metformin Fixed-Dose CombinationPioglitazoneTotal
Mean273.7 ± 84.8278.8 ± 86.4276.2 ± 85.5
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Wainstein J, Katz L, Engel SS, Xu L, Golm GT, Hussain S, O'Neill EA, Kaufman KD, Goldstein BJ. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2012 May;14(5):409-18. doi: 10.1111/j.1463-1326.2011.01530.x. Epub 2011 Dec 22. PubMed 22059736 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2008 to primary completion in Oct 2009, 20 months.

Results were first posted in Oct 2010, 11 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2007
First posted
Sep 21, 2007
StartActual
Jan 26, 2008
Primary completionActual
Oct 23, 2009
CompletionActual
Oct 23, 2009
Results first posted
Oct 18, 2010
Last update
Jun 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00532935
Responsible party
Sponsor
First posted
Sep 21, 2007
Start date
Jan 26, 2008
Primary completion
Oct 23, 2009
Completion
Oct 23, 2009
Results posted
Oct 18, 2010
Last update
Jun 9, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitagliptin · Metformin

Start the discussion